Drug Trial Radar · NCT06079372
Phase 3 Study of ALXN1850 in Pediatric Participants With HPP Previously Treated With Asfotase Alfa
Last checked: Nov 20, 2026Latest source record: May 5, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
43
Actual
Start
Apr 2, 2024
Primary completion
Jul 23, 2025
Study completion Feb 29, 2028
Sponsor
- Lead sponsor
- Alexion Pharmaceuticals, Inc.AstraZeneca (AZN)
- Sponsor type
- Industry
- First posted
- Oct 12, 2023
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 2 years, up to 11 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The primary purpose of this study is to assess the safety and tolerability of ALXN1850 versus asfotase alfa in pediatric participants with HPP previously treated with asfotase alfa.
Conditions
- Hypophosphatasia
Interventions
ALXN1850Drug
ALXN1850 will be administered via subcutaneous (SC) injection.
asfotase alfaDrug
Asfotase alfa will be administered via SC injection.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of Participants with Treatment-emergent Adverse Events (TEAEs)Time frame: Baseline Through Day 169
Locations
21 sites in 7 countries. Site status is shown where the registry gives one.
Research Site
Hartford, Connecticut
Research Site
Baltimore, Maryland
Research Site
Minneapolis, Minnesota
Research Site
Kansas City, Missouri
Research Site
Durham, North Carolina
Research Site
Nashville, Tennessee
Research Site
Mar del Plata, Argentina
Research Site
South Brisbane, Australia
Research Site
Ottawa, Ontario, Canada
Research Site
Bunkyō City, Japan
Research Site
Minatoku, Japan
Research Site
Suita-shi, Japan
Research Site
Yonago-shi, Japan
Research Site
Altındağ, Turkey (Türkiye)
Research Site
Ankara, Turkey (Türkiye)
Research Site
Edirne, Turkey (Türkiye)
Research Site
Erzurum, Turkey (Türkiye)
Research Site
Istanbul, Turkey (Türkiye)
Research Site
Birmingham, United Kingdom
Research Site
Manchester, United Kingdom
Research Site
Sheffield, United Kingdom
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.